BACKGROUND: The aim of our study was to assess the effect of pretreatment with cilostazol and rosuvastatin combination before elective percutaneous coronary intervention (PCI) on peri-procedural myocardial injury (PPMIJ). METHODS: We randomly assigned 172 patients with stable angina pectoris scheduled for elective PCI to pre- treatment withCilostazol 200mg and Rosuvastatin 40 mg (group 1), or to pretreatment with Rosuvastatin 40 mg group (group 2). The primary end-point was the occurrence of PPMIJ defined as any cardiac troponin I (Tn I) level elevated above the upper normal limit (UNL). The occurrence of peri-procedural myocardial infarction (PPMIN) was defined as a post-procedural increase in cTnI level ≥ 5 times above the UNL. RESULTS: There was no significant difference in baseline characteristics between group 1 (n = 86) and group 2 (n = 86). The rate of PPMIJ (21% vs. 24%, p = 0.58) and PPMIN (2.3% vs. 7%, p = 0.27) were similar between the two study groups. Subgroup analysis performed on those patients without statin therapy before PCI (53 patients in group 1 and 50 patients in group 2) showed that the incidence of PPMIJ was significantly lower in the group 1 patients without chronic statin treatment [17% (9/53) versus 34% (17/50); p = 0.04], but the rate of PPMIN was similar between the two groups for those patients without chronic statin treatment [1.9% (1/53) versus 10% (5/50); p = 0.07]. CONCLUSIONS: We found that adjunct cilostazol and rosuvastatin pre-treatment did not significantly reduce PPMIJ after elective PCI in patients with stable angina pectoris. However, adjunct cilostazol pre-treatment could reduce PPMIJ in patients without chronic statin therapy before elective PCI. KEY WORDS: Cilostazol; Myocardial injury; Percutaneous coronary intervention; Statin.
RCT Entities:
BACKGROUND: The aim of our study was to assess the effect of pretreatment with cilostazol and rosuvastatin combination before elective percutaneous coronary intervention (PCI) on peri-procedural myocardial injury (PPMIJ). METHODS: We randomly assigned 172 patients with stable angina pectoris scheduled for elective PCI to pre- treatment with Cilostazol 200mg and Rosuvastatin 40 mg (group 1), or to pretreatment with Rosuvastatin 40 mg group (group 2). The primary end-point was the occurrence of PPMIJ defined as any cardiac troponin I (Tn I) level elevated above the upper normal limit (UNL). The occurrence of peri-procedural myocardial infarction (PPMIN) was defined as a post-procedural increase in cTnI level ≥ 5 times above the UNL. RESULTS: There was no significant difference in baseline characteristics between group 1 (n = 86) and group 2 (n = 86). The rate of PPMIJ (21% vs. 24%, p = 0.58) and PPMIN (2.3% vs. 7%, p = 0.27) were similar between the two study groups. Subgroup analysis performed on those patients without statin therapy before PCI (53 patients in group 1 and 50 patients in group 2) showed that the incidence of PPMIJ was significantly lower in the group 1 patients without chronic statin treatment [17% (9/53) versus 34% (17/50); p = 0.04], but the rate of PPMIN was similar between the two groups for those patients without chronic statin treatment [1.9% (1/53) versus 10% (5/50); p = 0.07]. CONCLUSIONS: We found that adjunct cilostazol and rosuvastatin pre-treatment did not significantly reduce PPMIJ after elective PCI in patients with stable angina pectoris. However, adjunct cilostazol pre-treatment could reduce PPMIJ in patients without chronic statin therapy before elective PCI. KEY WORDS: Cilostazol; Myocardial injury; Percutaneous coronary intervention; Statin.
Authors: Matthias Briel; Gregory G Schwartz; Peter L Thompson; James A de Lemos; Michael A Blazing; Gerrit-Anne van Es; Meral Kayikçioglu; Hans-Richard Arntz; Frank R den Hartog; Nic J G M Veeger; Furio Colivicchi; Jocelyn Dupuis; Shinya Okazaki; R Scott Wright; Heiner C Bucher; Alain J Nordmann Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: Joseph B Selvanayagam; Italo Porto; Keith Channon; Steffen E Petersen; Jane M Francis; Stefan Neubauer; Adrian P Banning Journal: Circulation Date: 2005-02-21 Impact factor: 29.690
Authors: Mark B Nienhuis; Jan Paul Ottervanger; Henk J G Bilo; Bert D Dikkeschei; Felix Zijlstra Journal: Catheter Cardiovasc Interv Date: 2008-02-15 Impact factor: 2.692
Authors: A K Rao; C Pratt; A Berke; A Jaffe; I Ockene; T L Schreiber; W R Bell; G Knatterud; T L Robertson; M L Terrin Journal: J Am Coll Cardiol Date: 1988-01 Impact factor: 24.094
Authors: Joseph Longo; Aleksandra A Pandyra; Paweł Stachura; Mark D Minden; Aaron D Schimmer; Linda Z Penn Journal: Mol Oncol Date: 2020-08-25 Impact factor: 6.603